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ABSTRACT 
BACKGROUND Both the CHADS2 and CHA2DS2-VASc scores are well-validated in 
Western populations for predicting risk of stroke among patients with atrial 
fibrillation (AF). There is some uncertainty as to which risk score is best to guide 
optimal anticoagulant therapy among Asian populations with AF. 
METHODS A systemic literature search of Cochrane library, Scopus, and PubMed 
databases was conducted using search terms: atrial fibrillation, CHADS2 and 
CHA2DS2-VASc. Stroke/thromboembolism (TE) outcome events at low, moderate, 
and high risk groups were compared in relation to both scores. Statistical 
analyses were performed using Revman5.3 software.   
RESULTS 493 records were retrieved, of which 6 cohort studies focusing on 
patients from Asian regions were finally appraised and included. Absolute event 
rates were usually lower when patients were categorized as CHA2DS2-VASc of 0-1, 
rather than CHADS2 of 0-1, respectively. Meta-analysis revealed that when 
compared with the CHA2DS2-VASc score, there was a 1.71-fold elevated risk of 
stroke when patients were stratified as ‘low risk’ using a CHADS2 score=0, or a 
1.40-fold increase with a CHADS2 score=1. A 1.19-fold elevated event rate was 
observed amongst CHADS2 score ≥2 compared to CHA2DS2-VASc, but the total 
stroke/TE events were numerically higher in patients categorized as 
CHA2DS2-VASc ≥2.  
CONCLUSION The CHA2DS2-VASc score is superior to the CHADS2 score in 
identifying ‘low risk’ East Asian AF patients. Rather than a categorical approach, 
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Asian guidelines should adopt a 2 step approach, by initially identifying the truly 
low risk patients, following which effective stroke prevention can be offered to 
those with ≥1 additional stroke risk factors. 
 
KEYWORDS: Atrial Fibrillation; CHA2DS2-VASc; CHADS2; Asia  
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1. Introduction 
 
Atrial fibrillation (AF) is a common cardiac arrhythmia conferring an increased 
risk of stroke and thromboembolism (TE), and patients with AF-related stroke 
have an even worse prognosis than patients without AF, with longer 
hospitalizations, more disability and higher in-hospital mortality [1]. Despite a 
five-fold increased risk of stroke overall among AF patients, this risk is 
heterogeneous, depending on the presence and absence of several stroke risk 
factors.  
 
Given the need for estimating the risk of stroke/TE, clinical risk stratification 
schemes have been recommended to assist the clinician in selecting optimal 
thromboprophylaxis for appropriate individuals. The CHADS2 (Congestive heart 
failure, Hypertension, Age ≥75 years, Diabetes, previous Stroke) score which was 
initially derived from amalgamation of the Atrial Fibrillation Investigators’ and 
Stroke Prevention in Atrial Fibrillation Investigators’ Schema[2], is 
recommended in the American College of Chest Physicians (ACCP) and Canadian 
Cardiovascular Society guidelines[3, 4]. The recently proposed CHA2DS2-VASc 
(Congestive heart failure, Hypertension, Age ≥75 years, Diabetes, previous Stroke, 
Vascular disease, Age 65-74 years, Sex category [female]) score is now 
recommended by the American College of Cardiology/American Heart 
Association/Heart Rhythm Society (ACC/AHA/HRS), European Society of 
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cardiology (ESC), and National Institute for Health and Care Excellence 
(NICE)[5-7]. However, most validation studies have been in Western populations, 
and some uncertainty is evident for the selection of which score to guide optimal 
anticoagulant therapy among Asian populations with AF [8]. Thus, many 
clinicians in Asian countries prefer to the older CHADS2 score, which is perceived 
to be simple and easy to use.  
 
Nonetheless, it has been recognized that even patients categorized as low-risk by 
a CHADS2 of 0 are not necessarily at low risk of stroke, and the CHA2DS2-VASc 
score is often best to identify patients at “truly low risk” of stroke/TE [9, 10].  
 
Given the uncertainty over which score is best in Asian patients with AF, our 
objective was to perform a systemic review and meta-analysis of available 
studies to compare CHADS2 and CHA2DS2-VASc scores for risk stratification and 
second, to establish if which score has a better performance in identifying ‘truly 
low risk’ Asian patients with AF.   
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2. Methods 
 
Inclusion and Exclusion Criteria 
The following inclusion criteria were used for study selection: 1) Types of studies: 
randomized controlled trials (RCT) or observational cohort studies focusing on 
the CHADS2 and CHA2DS2-VASc scores for predicting the risk of stroke/TE; 2) 
Types of participants: AF patients from East Asian regions, including China, 
Taiwan, Japan, Korea; 3) Types of Interventions: No anticoagulation therapy; 4) 
Types of outcome measures: primary endpoints of ischemic stroke, TE, or both. 
Exclusion criteria were as follows: 1) Duplicated report on a same cohort; 2) 
Certain publication types, such as conference abstracts, letters, comments, case 
reports, and editorials [as we wished to focus on peer reviewed, robust published 
data]; 3) Studies not published in English. 4) Data presented for a population 
from regions outside East Asia, or the original source of study was not specified. 
5) Study population of <300 people, and the mean follow-up duration < 1 year 
[This was to avoid use of underpowered data].   
 
2.1 Literature Search 
Comprehensive literature searches were undertaken using Cochrane library, 
PubMed and Scopus databases for studies published between January 1, 2010 
and March 1, 2015, in view of the first research on CHA2DS2-VASc being 
published in 2010. Search terms included “atrial fibrillation”, “CHADS2” and 
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“CHA2DS2-VASc”. The electronic search was carried out for peer-reviewed 
journals, and some further additional data not identified in the electronic 
database were collected from other data resources, especially some original data 
was absent in the published articles. Specifically, we contacted with the 
corresponding authors to get the original data not reported in the published 
articles.    
 
2.2 Data Extraction 
All literature retrieved by the search strategy were screened by two reviewers 
(QX and SC) independently. The first sift-prescreening was performed by reading 
titles and abstracts to select studies for further data extraction. The second 
sift-selection was undertaken by comprehensively reviewing the full text to check 
if they reported the stroke/TE event rates or number at each points of CHADS2 
and CHA2DS2-VASc scores, and the original region of participants. Articles 
meeting the eligibility criteria were selected after review of full text.  
 
Data were extracted from each eligible study or calculated from the data 
presented, including the baseline characteristics of participants, follow-up 
duration, stroke/TE event rates or number for each point of both scoring system.  
Study endpoints, for example, ischaemic stroke, was taken as that defined in 
respective individual studies.  If the event number was unavailable in the full 
text or by contacting the corresponding authors, it was calculated by using the 
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following formula: Event number = (Total patient number) x (Event rate [per 100 
patient years]) x (Follow-up duration [years]). Discrepancies were resolved by 
consensus or, if necessary, through discussion or consultation with a third 
reviewer (KS). 
 
2.3 Quality Assessment and risk of bias  
Newcastle-Ottawa Scale were used for assessing the quality of all included cohort 
studies in this meta-analysis, involving selection of cohorts, comparability of 
cohorts, and assessment of outcome[11]. Both risk of bias and quality of included 
studies were evaluated by two reviewers (QX and SC) independently. 
 
2.4 Statistical Analysis 
Statistical analyses were performed using Review Manager Version 5.3 
(Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). 
Scores of 0, 1 and ≥ 2 were defined as the low, moderate, and high risk categories, 
respectively, for each scoring system. Stroke/TE events were measured as 
dichotomous outcome variables, compared between the same risk categories 
according to CHADS2 and CHA2DS2-VASc scores. Relative risk (RR) was calculated 
and presented with 95% confidence interval (CI) for the summary estimates. In 
view of the heterogeneity between included studies, appropriate statistical 
models, fixed-effect or random-effect models, were selected to ensure that the 
various statistics were estimated correctly. Cochran’s chi-square test and I2 
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statistic were measured to evaluate the heterogeneity between included studies. 
Cochran’s chi-square test was used to find out whether the observed difference 
may be due to chance alone. A low P-value means significant heterogeneous 
results among different study, with a cut-off at 0.10.  The I2 statistic can describe 
the percentage of total variation across the studies that are due to significant 
heterogeneity rather than random chance. If I2 statistic is higher than 75%, it 
suggests that there is considerable heterogeneity among these studies. The 
correction for publication bias was assessed by funnel plot analyses. Statistical 
significance was set at a P-value < 0.05.       
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3. Results 
 
A total of 493 records were identified through above mentioned literature search 
strategy. After removing duplicates, we extracted 238 records for screening.  
Following this, 201 were excluded by reviewing title or abstract and full texts of 
the remaining 37 articles were retrieved for further review if they met the 
predetermined criteria. Finally, six eligible studies were identified and included 
in the present meta-analysis [12-17]. The literature search flow diagram is 
shown in Figure 1. 
 
3.1 Study Characteristics 
Patient characteristics from each included study were shown in Table 1. In the 
present study, data from 31539 AF patients (15271 females, 48.4%) were pooled 
for further analyses. Among these studies, two population cohorts were from 
Taiwan nationwide database, focusing on non-valvular AF patients [15], and AF 
patients with end-stage renal dysfunction (ESRD) [12], respectively. In the 
Japanese study of Suzuki et al., data were pooled from Shinken Database, 
J-RHYTHM Registry, and Fushimi AF Registry to identify the ischemic stroke rates 
in Japanese non-valvular AF patients without anticoagulant therapy[17].        
 
3.2 Event rates 
The total event rates of ischemic stroke/TE varied from 2.10 to 9.28 per 100 
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person-years in non-anticoagulated AF patients from different observational 
cohorts (Table 1). Event rates at different points of the CHADS2 and 
CHA2DS2-VASc scores are shown in Figure 2.  
 
In the Taiwan nationwide cohort enrolling AF patients with ESRD, the overall 
incidences of stroke /TE were higher on the basis of both scores, compared with 
those observed in other cohorts[12]. In the cohort of Japanese non-valvular 
paroxysmal AF patients who were not receiving anticoagulation therapy, the 
event rates were even higher at CHADS2 of 3, ≥4, and CHA2DS2-VASc of 5, ≥6 [14]. 
In the low risk category of three included studies, event rates based on 
CHA2DS2-VASc score were lower, compared those based on CHADS2 score. All 
event rates in the moderate risk category were lower on the basis of 
CHA2DS2-VASc score, as shown in Figure 2. 
  
3.3 Quality Assessment 
Assessment of the quality of all included studies was undertaken using NOS 
items designed for cohort studies. These studies were of high quality presented 
with 8 or 9 stars, as shown in Table 3. Three papers [12, 14, 17] received three 
stars in the selection items due to pooled analysis or selecting particular AF 
patients such as paroxysmal AF patients and AF patients with ESRD. A possible 
absence of publication bias was observed using a funnel plot (Figure 3).   
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3.4 Data synthesis 
(a) Low risk category 
In a pooled analysis of all included patients at low risk of ischemic stroke/TE, a 
very low heterogeneity was observed, as reflected by I2 statistic of 10%, 
indicating that the variability between these studies was acceptable. Among all 
included AF patients, there were 4942 patients considered at very low risk with a 
CHADS2 score of 0, but 259 (5.2%) experienced ischemic stroke/TE events 
during follow-up. In 1774 patients with CHA2DS2-VASc score of 0, only 45 (2.5%) 
had ischemic stroke/TE events during follow-up. When data were pooled across 
these studies, low risk patients with CHADS2 score of 0 had a significant higher 
risk of ischemic stroke/TE endpoints compared to those ‘low risk’ patients 
defined with a CHA2DS2-VASc score of 0 (RR, 1.71; 95%CI: 1.26-2.31 ), as shown 
in Figure 4. 
 
(b) Moderate risk category 
In the pooled analysis of patients with moderate risk of ischemic stroke/TE, 
there was no heterogeneity between these included studies in view of the I2 
statistic of 0%, indicating that all these studies were comparable when we 
performed this pooled analysis. Among 7449 AF patients with CHADS2 score of 1, 
689 (9.2%) experienced ischemic stroke/TE during observation period, 
compared to 171 (5.2%) of 3281 AF patients categorized as CHA2DS2-VASc score 
of 1. The risk of ischemic stroke/TE risk was higher when patients were 
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stratified with CHADS2 score of 1, compared with when categorized by a 
CHA2DS2-VASc score of 1 (RR, 1.40; 95%CI: 1.20-1.64), as shown in Figure 5.  
 
(c) High risk category 
When comparing the incidence of events in the high risk category on the basis of 
both scores, high heterogeneity was observed, with an I2 statistic of 83%. 
Therefore, a random effects model was selected to carry out the pooled analysis, 
and the results should be interpreted cautiously.  
 
When CHA2DS2-VASc score ≥2 was used to identify patients at high risk of 
ischemic stroke/TE, there were more patients (n=3387; 12.7%) experiencing 
events during follow-up. The pooled analysis found a higher risk of ischemic 
stroke/TE in patients with CHADS2 score ≥2 (RR, 1.19; 95%CI: 1.02-1.38), but 
the total number of stroke/TE events and rates were higher among all included 
patients when categorized as CHA2DS2-VASc score ≥2.  
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4. Discussion 
 
In this systematic review and meta-analysis, our principal finding was that event 
rates of ischemic stroke/TE were usually lower in patients categorized as 
low-moderate risk by use of the CHA2DS2-VASc score, when compared with those 
based on CHADS2 score. Second, the pooled analysis indicated that CHA2DS2-VASc 
score was particularly helpful to identify AF patients at low-risk among Asian 
populations. Thus, those patients with CHADS2 score of 0 or 1 should be further 
stratified using CHA2DS2-VASc score for predicting stroke/TE risk.  
 
4.1 Event rates 
The differences in ischemic stroke/TE event rates between included studies 
reflect the different patient cohorts and the details of methodology, such as the 
length of follow-up and the intervention of participants. For example, Chao et al. 
included AF patients with ESRD requiring dialysis, and the event rates were even 
higher at each point compared to other cohorts[12]. Despite this, all included 
studies were homogenous for the comparison of ischemic stroke/TE events in 
low-moderate categories between both scores, as reflected by low I2 statistics of 
0% and 10%.  
 
The overall ischemic stroke/TE rates in non-anticoagulated AF patients from 
Asian countries, ranged from 2.10 to 9.28 per 100 person-years, were 
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comparable to (or even higher than) corresponding rates published for 
Caucasians. Indeed, the reported rate of AF-related stroke was similar at 13.0% 
to 15.4% in community-based cohort studies from China, Japan, Singapore, and 
Taiwan[18].     
 
4.2 CHADS2 versus CHA2DS2-VASc score 
Both CHADS2 and CHA2DS2-VASc scores are useful risk stratification tools for 
predicting ischemic stroke/TE. More recently, the CHA2DS2-VASc score has been 
shown to have a better performance, as presented by higher C-statistics in 
several cohort studies [12, 13, 16, 19, 20]. A previous meta-analysis 
demonstrates an approximately 6-fold increased risk of stroke/TE in AF patients 
with CHA2DS2-VASc of ≥2, which was significantly better than the 3-fold 
increased risk predicted by a CHADS2 score of ≥2[21].  However, no significant 
difference in predictive ability between both scores has been found in one 
Japanese cohort study [14]. Due to the traditional belief of a higher bleeding risk 
but lower stroke risk among Asian populations, the CHADS2 score, but not the 
CHA2DS2-VASc score is widely recommended by AF guidelines or expert 
consensus in many Asian countries, such as Japan. In the APHRS guidelines, the 
CHA2DS2-VASc score is the recommended risk scoring system [22]. 
 
Given that the risk profile of AF patients is not static but a dynamic one, a 
potential bias on the incidence of ischemic stroke/TE will be introduced when 
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the methodology of study differs. As demonstrated in the Taiwanese cohort, even 
patients with CHADS2 of 0 or 1 can have CHA2DS2-VASc scores ranging from 0 to 
4, with an increasing incidence of ischemic stroke from 2.1 to 4.7 per 100 
person-years[12]. This is consistent with the results from the Danish nationwide 
cohort study, which has shown that patients with CHADS2 of 0 can be subdivided 
by CHA2DS2-VASc scores into 0 to 4, with stroke/TE rates from 0.84 to 3.2 per 
100 person-years at one-year follow-up[9]. Another study reported that among 
AF patients who had indication for anticoagulation by CHA2DS2-VASc score but 
categorized as “not for anticoagulation” using the Canadian Cardiovascular 
Society algorithm based on the CHADS2 score, the overall incidence of ischemic 
stroke/TE was 4.32 per 100 person-years[23]. In view of these findings, patients 
with CHADS2 score of 0 are not necessarily at “low risk” for the development of a 
potentially fatal or disabling stroke.    
 
The present analysis shows that similar to other European cohorts, the 
CHA2DS2-VASc score is useful in identifying truly low risk AF patients from the 
Asian population [20, 24-26]. This is further reinforced by another Taiwanese 
cohort study which demonstrated a better performance of CHA2DS2-VASc score 
for refining low risk Asian AF patients, comparing with another risk scoring 
system, the anticoagulation and risk factors in atrial fibrillation (ATRIA) 
score[10].    
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For patients with significant/high risk of stroke/TE, as predicted by 
CHA2DS2-VASc or CHADS2 score of ≥2, decision making on recommending 
anticoagulation is easy regardless of which score should be used, as the 
therapeutic decision is similar (i.e. anticoagulation) whether the score is 2,3,4 or 
higher. For those patients with a CHADS2 score of 0 or 1, efforts should be made 
to identify individuals who can potentially benefit from anticoagulation therapy. 
Thus, the focus should be drawn on the truly low-risk patients and those with 
one additional risk factor (CHA2DS2-VASc score of 1 in male, 2 in female), where 
anticoagulation is also likely to benefit [27, 28].  
 
The present analysis clearly provides compelling evidence supporting use of the 
CHA2DS2-VASc score for stroke risk stratification in Asian patients with AF, given 
its refinement of identifying ‘truly low risk’ patients. Asian physicians have 
generally been unconvinced by the applicability of non-Asian data, which is why 
we need to specifically show that the CHA2DS2-VASc does work better in 
identifying low risk patients in the Asian populations.   
 
Rather than a categorical (i.e. low/moderate/high risk) approach to stroke risk 
and treatment decisions, the ESC and NICE guidelines recommend a 2 step 
approach. The 1st step is to identify ‘low risk’ patients (CHA2DS2-VASc score of 0 
in males, 1 in females) who do not need any antithrombotic therapy.  The next 
step is to offer effective stroke prevention (which is oral anticoagulation) to those 
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with ≥1 additional stroke risk factors, irrespective of the CHA2DS2-VASc score 
value. 
    
4.3 Limitations 
Several limitations should be addressed in this present study. Firstly, limited 
eligible data can be available for this meta-analysis. We extracted only 6 cohort 
studies from China, Japan, and Taiwan, respectively. No data from other Asian 
countries can be included for pooled analysis, such as Singapore, Malaysia, Korea, 
etc. Thus, our findings are not representative for the whole Asia. Second, a high 
heterogeneity was observed when comparing the ischemic stroke/TE events in 
high-risk patients between both groups. Nonetheless, this study particularly 
focuses on the predictive ability of low-moderate risk of ischemic stroke/TE 
among Asian AF patients. Finally, the ‘truly low-risk’ patients are a CHA2DS2-VASc 
score of 0 in male and 1 in female, with stroke event rates of 0.49 per 100 
person-years at 1-year[28].  Nevertheless, given that all published data thus far 
make no similar definition, only patients with CHA2DS2-VASc score of 0 were 
stratified into the low risk category in the present meta-analysis. Further studies 
are warranted to identify ‘truly low risk’ patients based on a more detailed 
stratification for males and females. 
 
5. Conclusion 
In conclusion, the CHA2DS2-VASc score is superior to the CHADS2 score in 
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identifying ‘truly low risk’ Asians patients with AF.  Rather than a categorical (i.e. 
low/moderate/high risk) approach to stroke risk and treatment decisions, Asian 
guidelines should adopt a 2 step approach, by initially identifying the low risk 
patients (using the CHA2DS2-VASc score) who do not need any 
thromboprophylaxis, following which effective stroke prevention can be offered 
to those with ≥1 stroke risk factors. 
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Figure 1.  Study Search Diagram 
 
Figure 2.  Event rates of ischemic stroke/TE at each point based on CHADS2 and CHA2DS2-VASc scores 
 
Figure 3.  Funnel plot shows all studies included in the bias analysis. 
 
Figure 4.  
Comparison of ischemic stroke/TE events in the low risk category on the basis of CHADS2 and CHA2DS2-VASc scores 
 
Figure 5.  
Comparison of ischemic stroke/TE events in the moderate risk category on the basis of CHADS2 and CHA2DS2-VASc scores 
 
Figure 6.  
Comparison of ischemic stroke/TE events in the high risk category on the basis of CHADS2 and CHA2DS2-VASc score 
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Table 1. Patient characteristics in the included studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AF = Atrial fibrillation; NVAF = Non-valvular AF; ESRD = End stage of renal dysfunction; TE = Thromboembolism; NA = not available 
*Number of patients without anticoagulant therapy 
# The percentages of patients aged 20-64 yrs, 65-74 yrs, ≥75yrs were 36.7%, 30.9%, and 32.4%, respectively. 
¶ The range of event rates at each point of CHADS2 and CHA2DS2-VASc 
®Data were pooled from the Shinken Database (n=1,099), J-RHYTHM Registry (n=1,002), and Fushimi AF Registry (n=1,487)
Study ID Data source 
Study 
cohort 
Follow-up 
Patients 
Number*(n) 
Female 
(%) 
Age 
(years) 
Outcome 
of interest 
Total event 
rate (number) 
Chao, TF 2014[12] 
Taiwan (Jan 
1996-Dec 2011) 
AF with 
ESRD 
13m 
(median) 
10,999 53.8 
71.0±1
1.1 
Ischemic 
stroke 
6.9 (1,217) 
Guo, YT 2013 [13] 
China (Beijing, 
Nov2007-Jul 
2010) 
AF 
1.9y 
(median) 
885 26.6 
75 
(63-83) 
TE 3.7 (NA) 
Komatsu, T 2014 [14] 
Japan (Jun 
1995-Aug 2008) 
Paroxysmal 
NVAF 
53m 
(mean) 
332 32.5 65±13 
Ischemic 
stroke/TE 
2.1 (NA) 
Lin, YL 2011 [15] 
Taiwan 
(1997-2008) 
NVAF 
1637d 
(median) 
7,920 45.9 ≥20# 
Ischemic 
stroke 
0.35-6.52¶ 
(NA) 
Siu, CW 2014 [16] 
China (Hong 
Kong Jul 
1997-Dec 2011) 
NVAF 
3.19 
(mean) 
7,815 53.2 
76.9±1
2.5 
Ischemic 
stroke 
9.28 (1795) 
Suzuki, S 2015 [17] 
Japan (Shinken, 
J-Rhythm, 
Fushimi) 
NVAF NA 3,588® 33.9 
68.1±1
3.5 
Ischemic 
stroke 
0.35-7.24¶ 
(69) 
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 Table 2. Ischemic stroke/TE event rates at low/moderate risk category based on CHADS2 and CHA2DS2-VASc scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Study ID 
Ischemic stroke/TE event rates (per 100 person-years) 
CHADS2=0 CHA2DS2-VASc=0 CHADS2=1 CHA2DS2-VASc=
1 
Chao, TF 2014 [12] 2.0 2.1 3.5 2.4 
Guo, YT 2013 [13] 0 0 2.9 0.9 
Komatsu, T 2014 [14] 0.21 0 0.93 0.60 
Lin, YL 2011 [15] 0.45 0.35 0.97 0.50 
Suzuki, S 2015 [17] 0.54 0.53 0.93 0.55 
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Table 3. Quality assessment of all included studies 
 
 Selection Comparability Outcome 
Chao, TF 2014[12] 
☆☆☆ ☆☆ ☆☆☆ 
Guo, YT 2013 [13] 
☆☆☆☆ ☆☆ ☆☆☆ 
Komatsu, T 2014 [14] 
☆☆☆ ☆☆ ☆☆☆ 
Lin, YL 2011 [15] 
☆☆☆☆ ☆☆ ☆☆☆ 
Siu, CW 2014 [16] 
☆☆☆☆ ☆☆ ☆☆☆ 
Suzuki, S 2015 [17] 
☆☆☆ ☆☆ ☆☆☆ 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
30 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
31 
 
Fi.g 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
32 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
33 
 
Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4  
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Fig. 5  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
39 
 
 
Fig. 6 
